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Abstract:  Aims: Since 2001 guidelines recommend statin treatment in most patients with diabetes. We investigated   
secular changes in initiation and persistence to statin treatment during a 10-year period in a nationwide cohort of patients 
initiating glucose-lowering medication (GLM). 
Methods: All Danish citizens 30 years and older who claimed prescriptions of GLM between 1997 and 2006 were   
identified from nationwide registers of drug dispensing from pharmacies and hospitalizations, and followed until 2006. 
Statin treatment was registered if a prescription was claimed during the period. By logistic regression we analyzed factors 
related to initiation and persistence to statin treatment. 
Results: In total 128,106 patients were included. In 1997 only 7% of the patients receiving GLM claimed statins within the 
first year after GLM initiation. Despite increasing statin prescriptions the following years, only 62% were using statins at 
the end of follow up. The chance of ever receiving statins was lowest if not initiated within 180-days following the first 
purchase of GLM (OR 0.75, 95% CI 0.74-0.76). A previous myocardial infarction was associated with increased statin 
treatment (OR 4.51; 95% CI 4.31 - 4.71), while low income was associated with lower use of statins (OR 0.68; 95%CI 
0.66-0.72). Between 75-85 % of the patients who initiated statins treatment were persistent to treatment by 2007.  
Conclusions: In spite of increasing use of statins in diabetes patients over time, many patients remain untreated. Early  
initiation of statin treatment in diabetic patients and focus on patients with low socioeconomic status is needed to give 
long-term benefits. 
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INTRODUCTION 
  The benefit of statin treatment in the diabetes population 
is well established [1-7]. American and European guidelines 
recommend lipid lowering therapy in diabetes patients be-
cause they consider diabetes as a cardiovascular risk equiva-
lent to established coronary disease since 2001 [8-10]. Nev-
ertheless, several cohort studies have observed an insuffi-
cient use of statins in target populations [11-13]. 
  An underuse of recommended treatment can be related to 
several factors; i.e. lack of initiation of treatment, or due to  
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interruption of treatment by the patient or in relation to con-
current medical or socioeconomic causes. Hence, it is impor-
tant to identify which of these factors may be modified to 
improve adherence to treatment. 
  The aim of this study was to elucidate the extent of stat-
ins use over the last 10-years in the diabetic population in 
Denmark. The study included all Danish citizens receiving 
glucose-lowering medicine (GLM) and evaluated initiation 
and persistence to statin treatment in a 10-year period. 
METHODS 
  All claimed prescriptions from pharmacies in Denmark 
have been registered in the Danish Registry of Medicinal 
Products Statistics since 1995. All drugs are classified   
according to an international classification of drugs, the   Statin Use in Diabetes Patients in Denmark  The Open Cardiovascular Medicine Journal, 2009, Volume 3    153 
Anatomical Therapeutical Chemical (ATC) system, and the 
registry also includes information of date of dispensing,   
dosage, quantity dispensed and the affiliation of the physi-
cian issuing the prescription. All residents in Denmark are 
assigned a unique and permanent personal civil registration 
number which enables cross-linking between nationwide 
administrative registers at individual level, including data on 
residence and household income [14].  
  The Danish National patient Registry keeps records on 
all hospital admissions since 1978. Each admission is regis-
tered with 1 primary diagnosis, and if appropriate 1 and 
more secondary diagnoses, according to the International 
Classification of Diseases, the 8
th revision until 1994 (ICD-
8) and the 10
th revision (ICD-10) from 1994 [15].  
  The study cohort comprised all persons who claimed a 
prescription of GLM for the first time between 1997 and 
2006. First time purchase of GLM was used as a proxy for 
newly diagnosed type 2 diabetes. To identify first time users 
of GLM, patients who had purchased a GLM before 1997 
were excluded from the study.  
Use of statins was followed until the end of 2007.  
  Statins can not be purchased over the counter in Denmark 
and we identified whether a statin was prescribed within 30 
days from the first GLM purchased in each period and de-
fined those as patients receiving statin at start of GLM. Simi-
larly we identified patients receiving a statin within 180 days 
and 1 year from the first GLM prescription in each period, 
respectively, to identify patients with later initiation of statin 
treatment. Since treatment policies have changed throughout 
this period, the study period was divided in 4 intervals, 
where the last period corresponds to 2006. We calculated the 
period of days covered by a purchase of a statin based on the 
pack size, and assuming an average dose of 1 daily tablet. 
STATISTICAL ANALYSIS 
  To analyze factors determining early initiation of statin 
treatment and initiation within 180 days after commencing 
GLM we performed a multivariable logistic regression 
analysis. The regression analysis was adjusted for year of 
first GLM prescription claim (with 1997 as reference), age, 
sex, previous myocardial infarction (MI), insulin treatment 
as the first anti-diabetes medicine and income. 
  Income was graded in quartiles  according to gross 
household income, obtained from administrative registers 
how was income data obtained?. Patients who had been hos-
pitalized with a MI as primary diagnosis (ICD codes I21 or 
I22 and ICD-8 code 410 for MI before 1994) in the 19-year 
period before inclusion were identified as “previous MI”. 
Occurrence of MI during the study period was included as 
co-morbidity of interest. 
  Previous studies have demonstrated the importance of 
long-term adherence to statin treatment to optimize survival 
rates [16, 17]. Adherence can be defined in different ways, 
most often it has been defined as the time-course until treat-
ment is paused, but we have shown in a previous study from 
our group, that many patients who pause their medication 
after a MI do restart the treatment even after several months 
cessation[18]. For this reason we performed 2 analyses. One 
approach was a calculation of the percentage of patients who 
were receiving statins at any time-point and in another 
analysis the time until a break in treatment of 30 or 90 days 
was estimated. This approach has been described in details 
previously [18].  
  Multivariable Cox regression analysis was used to iden-
tify risk factors for a poor adherence to statin treatment. 
RESULTS 
  In total, 5.6 million statin prescriptions were recorded for 
the entire period, from January 1, 1997 to December 31, 
2006 and of those, 1.4 million were purchased by 128,106 
patients who had a previous GLM prescription.  
  In the time period 1997 – 1999 only 3.6% of patients 
who initiated GLM treatment also claimed statins within 30 
days subsequently to GLM purchase (Table 1) increasing to 
Table  1.  Basal Characteristics for Patients Starting Statins after Commencing Glucose-Lowering Medications (GLM) in   
Denmark in the Period 1997-2006 
  1997-1999  2000-2002  2003-2005  2006 
Number  34 713  36 267  42 611  14 515 
Age 62  ± 14  59 ± 13  56 ± 13  54 ± 12 
Men, %  56.1  56.3  56.4  56.8 
Previous MI
a, %  7.8  8.5  8.7  8.8 
Previous stroke, %  6.96  7.73  7.81  7.79 
Insulinb, %  10.5  9.8  8.6  8.5 
Statin within 30 days after GLM
c, %  3.6  10.8  31.6  43.3 
Statin within 1 year after GLM
c, %  7.0  19.7  46.6  51.2 
a Previous acute myocardial infarction (MI) is considered when patients had a previous hospitalization with the diagnosis of a MI by the first claim of GLM. 
b Insulin refers to the proportion of patients taking insulin at the beginning of each observation period.  
c Purchase of statins is shown as the proportion of patients who were dispensed statins latest 30 days after their first GLM purchase or within 1 year after their first GLM purchase, 
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43.3% in 2006. The fraction of patients initiating statin 
treatment later than 30 days at any time after start of GLM 
increased only moderately (less than 5% per year), and no 
more than 62% of patients using GLM in total received statin 
treatment by the end of the study (Fig. 1). About 8% and 7% 
of the patients who claimed GLM had a previous MI and a 
previous stroke diagnosis, respectively. These numbers were 
constant throughout the observation period (Table 1).  
  The proportion of patients who claimed insulin as   
their first GLM during 1997 was 10.5%. This proportion 
decreased slightly in the following years (Table 1). Further-
more, persons using GLM were progressively younger 
throughout the study period. 
  Among all patients receiving GLM, 12 146 had suffered 
a MI and 10 886 a stroke. Table 2 shows the results of the 
multivariable logistic regression analysis on factors influenc-
ing initiation of statin treatment within 180 days from first 
prescription of GLM. Older patients were less likely to re-
ceive statins, with a reduction in OR decrease by 11 % for 
each 10-year increase in age. The chance that patients 
claimed statins after commencing GLM increased over the 
years, accordant with the inclinations of the curves depicted 
in Fig. (1). Furthermore, a previous MI was among the 
strongest predictors for initiation of statin treatment, OR 4.51 
(95% CI 4.31 – 4.71) while patients with a previous stroke 
were less likely to receive statins (OR 0.39 (95% CI 0.32 – 
0.42). Patients who were started on insulin as first GLM had 
a reduced likelihood of receiving statins with an OR of 0.54 
(95% CI 0.51 – 0.57). Age did not appear to influence the 
use of statins in patients started on insulin since it was not 
possible to identify a statistical interaction (p=0.12). 
 Table  3 shows an analysis on which factors determined a 
patient’s likelihood of receiving statins more than 3 months 
after commencing GLM. Use of insulin as the first GLM 
medication decreased the odds for commencing statins 
within the following year by 50%, while a previous MI 
markedly increased the chance of statins being prescribed 
within one year after the first claim of GLM. 
  Once commencing treatment with statins, patients main-
tained the treatment throughout the following years (Fig. 2). 
Most brakes in statin treatment occurred soon after initiation, 
but most patients restarted the treatment and more than 80% 
continued statin treatment in the following years (Fig. 2). We 
further analyzed elapsed time from the first statin prescrip-
tion until the treatment was withheld for 30 and 90-days, 
respectively. This analysis confirms a high adherence to the 
treatment. More than 3 years elapsed before the treatment 
was withheld for 30 days in 50% of the population and 
nearly 10 years before it was withheld for 90-days in 50% of 
the population (Fig. 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Cumulative frequency of patients who claimed a statin prescription after their first glucose-lowering medication purchase. 
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  To elucidate which factors determined a poor long-term 
persistence (break in treatment of 90 days), we performed a 
multivariable Cox regression analysis (Table 4). This analy-
sis shows that men had a poorer persistence to treatment than 
women, and that patients with previous MI and elderly had 
higher persistence to treatment. Furthermore, we found a 
linear gradient of increasing risk associated with lower in-
come. An equivalent Cox regression analysis for the period 
1997 to 2004 found a much stronger association of poor ad-
herence with lower income, with a HR 1.98 (CI 1.82 – 2.16, 
p<0.001) for the 2nd quartile and 2.11 (CI 1.62 – 2.75, p< 
0.002) for the lowest quartile.  
Table 2.  Logistic Regression of Covariates Related to Start of Statin Treatment within 180 Days after the First Purchase of   
Glucose-Lowering Medicine 
Covariate  Odds Ratio  95% CI  P 
AGE – PER 10 YEAR  0.89  0.88 - 0.90  <.0001 
MALE SEX  0.96  0.98 - 0.99  0.007 
1997-1999* 1     
2000-2002  1.73  1.68 - 1.78  <.0001 
2003-2005  2.27  2.23 – 2.31  <.0001 
2006  2.09  2.06 – 2.12  <.0001 
Previous MI
a  4.51  4.31 – 4.71  <.0001 
Previous stroke  0.39  0.32 – 0.42  < .0001 
Insulin treatment  0.54  0.51 – 0.57  <.0001 
Income (highest quartile)  1     
Income 3rd quartile  0.89  0.86 - 0.93  <.0001 
Income 2nd quartile  0.78  0.75 - 0.81  <.0001 
Income lowest quartile  0.68  0.66 - 0.72  <.0001 
a MI is myocardial infarction; *reference in logistic regression analysis. 
 
Table 3.  Logistic Regression of Factors Related to Start of Statin Treatment Later than 180 Days after the First Purchase of  
Glucose-Lowering Medicine 
Covariate  Odds Ratio  95% CI  p 
Age – per 10 years  0. 70  0.69 - 0.71  <.0001 
Male sex†  0.87  0.84 - 0.89  <.0001 
1997 - 1999*  1     
2000 - 2002   1.00  0.90 - 1.03  0.74 
2003 – 2005  0.83  0.82 – 0.84  <.0001 
2006  0.32  0.32 – 0.33  <.0001 
Previous MI
a  1.19  1.12 - 1.27  <.0001 
Previous stroke  0.74  0.69 – 0.79  <.0001 
Insulin treatment   0.47  0.45 - 0.50  <.0001 
Income (highest quartile)*  1     
Income 3
rd quartile  0.87  0.84 - 0.91  <.0001 
Income 2
nd quartile  0.61  0.69 - 0.74  <.0001 
Income lowest quartile  0.63  0.60 – 0.66  <.0001 
a MI is myocardial infarction; *reference in logistic regression analysis. † Women as reference. 156    The Open Cardiovascular Medicine Journal, 2009, Volume 3  Dominguez et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Proportion of patients receiving glucose lowering medication who were taking statins at any time-point since the first statin purchase, 
according to treatment period. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Elapsed time from the first statin purchase to a break in treatment of 30-days and a 90-days, respectively, according to period of 
treatment initiation. 
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Table 4.  Cox Proportional-Hazard Analysis of Covariates Influencing Poor Adherence to Statin Treatment (Break in Treatment of 
90 Days) in Patients Receiving Glucose Lowering Medication 
Covariates  Hazard Ratio  95% CI  p 
Age – per 10 years  0.85  0. 83 - 0.87  <.0001 
Male sex  1.15  1.11 - 1.19  <.0001 
1997 – 1999  1     
2000 – 2002  0.95  0.94 – 0.97  <.0001 
2003 – 2005  0.89  0.88 - 0.90  <.0001 
2006  0.74  0.75 - 0.76  <.0001 
Previous MI
a  0.80  0.75 - 0.85  <.0001 
Previous stroke  0.91  0.84 – 0.98  0.009 
Insulin treatment  0.91  0.85 - 0.97  0.005 
Income (highest quartile)  1     
Income 3
rd quartile  1.03  0.98 - 1.84  0.11 
Income 2
nd quartile  1.07  1.03 - 1.12  0.002 
Income lowest quartile  1.09  1.03 - 1.15  0.002 
a MI is myocardial infarction.  
  The first prescription was initiated by the general practi-
tioner in 91% of the cases. Accordingly, only 26% of the 
patients had a hospital admission in a 60-days period preced-
ing the purchase of the first statin prescription. Hence, a   
majority of hospitalized patients were discharged without a 
statin prescription. 
DISCUSSION 
  This is a nationwide study on the use of statins in patients 
initiating GLM in the period after 1997. In spite of an   
increasing initiation of statin treatment along with start of 
GLM, by the end of 2006, only 51% of the patients purchas-
ing GLM during the last observation year received statins. 
The tendency towards increasing statin initiation occurred 
slowly over the years. At the end of follow-up only 62% of 
the patients receiving GLM were treated with statins while, 
according to international guidelines from 2001[8], almost 
100% of them should receive statins (Fig. 1).  
 Donelly  et al. found that the poorest long-term adherence 
to statins in patients with diabetes occurred among younger 
patients, especially among those without cardiovascular dis-
ease[19], which is consistent with our observations. In ac-
cordance with Donelly’s and other studies, the presence of a 
previous MI increased the chance of receiving a statin in the 
diabetic population compared with patients without estab-
lished coronary heart disease [19-21]. Nevertheless, there is 
still room for improvement in the use of statin in patients 
with coronary heart disease both in Denmark [22, 23] and in 
European countries in general [24], especially taking into 
account that the cardiovascular risk in the diabetic popula-
tion is equivalent to that of the patients with a previous MI 
[25].  
  We found a linear gradient in decreased initiation of 
statin treatment according to socioeconomic status. This is 
an important observation that requires further attention. Pre-
vious studies, in Denmark and abroad, have demonstrated 
lower use of statins in coronary patients with lower socio-
economic status [23, 26-28]. In Denmark all citizens receive 
partial reimbursement by the government financed health 
security system, independent of employment status, income, 
age or participation in private health insurance systems. The 
policies regulating partial reimbursement have changed sev-
eral times during the study. One of these policy changes car-
ried a substantial reimbursement increase after 2002. Inter-
estingly, the most remarkable change in the pattern for early 
use of statins occurs from the period 2000-2002 to the period 
2003-2005 (Fig. 1), which may be associated with the 
change of policies in 2002, although there were other factors 
that may have influenced this evolution, such as international 
guidelines from 2001 recommending intensive lipid lowering 
in all diabetic patients[8]. In this context it is interesting that 
that the HR associated with lower income for the period 
1997-2004 were substantially higher than the HR for the 
entire period (Table 4), suggesting that income became less 
important for an adequate persistence to statins in the later 
years. These results altogether point to medicine pricing as a 
major factor for poorer adherence to statin treatment among 
patients with low socioeconomic status. 
  The reduced odds for receiving statins in patients com-
mencing on insulin as first GLM may be due to inclusion of 
patients with type 1 diabetes. Treatment with GLM and stat-
ins were generally initiated at general practices, reflecting 
the general practitioner’s important role in secondary pre-
vention. This study demonstrates the need for focus on sec-
ondary prevention after discharge for what condition?, since 
only a minority of patients receiving GLM after discharge 
subsequently initiated statin treatment. This is worrying and 
reflects low awareness on the subject among hospital physi-
cians caring for diabetic patients. Even though the study ac-158    The Open Cardiovascular Medicine Journal, 2009, Volume 3  Dominguez et al. 
counts for any cause of hospitalization, it is important to 
emphasize the importance of prescription of statins in dia-
betic patients shortly after hospitalization for acute coronary 
syndromes, as this leads to a higher adherence to statins [18]. 
Furthermore, prescription of statins shortly after hospitaliza-
tion has been demonstrated to improve their outcomes in 
clinical trials [29, 30], as well as in patients hospitalized with 
MI [27]. An increased prescription of statins shortly after 
diagnosis of type 2 diabetes has improved the outcome in the 
general population in U.K. [31]. 
  Given these difficulties with low adherence to statin 
treatment it is important to consider possible improving 
strategies. Several adherence programs in U.S. have been 
successful [32, 33]. One of them was based on claimed pre-
scriptions to identify prescribers as well as target patients, 
where prescribers were warned when their patients were   
not receiving statins. This approach improved adherence to 
statins and was cost-effective [32]. In another successful 
program, patients with diabetes received individualized   
telephonic counseling [33]. Identification of target patients 
based on claimed prescriptions and hospitalization diagnosis 
is feasible in Denmark and in other countries where prescrip-
tions are registered. Once identified it is possible to contact 
the patients as well as their primary care doctors. In most 
European countries this is a possible national approach.  
  This study has several limitations that are important to 
emphasize. We lack information about additional factors 
influencing the decision for initiation of statin treatment, the 
most important one being individual patient lipid levels. 
However, guidelines recommend low target lipid levels in all 
diabetic patients [8, 10, 34], and most patients do not reach 
those targets without pharmaceutical intervention. Thus, 
statin treatment is indicated for most diabetes patients. An-
other limitation is that we do not have information about 
patients that were intolerant to treatment or terminated 
treatment due to side-effects. Nor do we have information on 
patients with contraindications to treatment with statins. Pa-
tients with diabetes not taking GLM were not included in the 
study; therefore it is not possible to conclude on how exten-
sive the use of statins is in these patients. The exclusion of 
patients who had claimed GLM before 1997 does not war-
rant that patients who claimed GLM in 1997 and later on did 
so for the very first time. Some of these patients may have 
started GLM treatment earlier but through dieting and exer-
cise they might have achieved control of glycaemia and 
thereby, delayed the need for restarting GLM until further 
development of diabetes. Furthermore, in our study it is not 
possible to identify type 1 and type 2 diabetes among insulin 
consumers. Finally, our study did only identify prescription 
claims of statins, the predominant type of lipid lowering 
medication, but did not identify use of other types of lipid 
lowering drugs. How many patients were on fibrates or other 
lipid lowering drugs? 
  The criteria for the diagnosis of MI have changed 
through the observation period. The diagnosis of MI in   
the National Patient Registry has proved to be valid, with a 
sensitivity of 91% and a positive predictive value of 93% 
[35].  
  The main strength of the study is the completeness of 
data, including all diabetes patients receiving GLM treatment 
on nationwide level in Denmark. The main advantage of 
using GLM to identify diabetic patients is that the indication 
for treatment is specific for diabetes.  
CONCLUSIONS  
  Use of statins in the diabetic population receiving GLM 
in Denmark is insufficient. Older age predicts low initiation 
and low income predicts both low initiation and low persis-
tence. Once started, patients continue taking statins. For 
long-term benefits, focus should be based on improvement 
of initiation of statin treatment in patients with diabetes.   
Efforts on improvement of the use of statins in patients   
receiving GLM should be focused on general practitioners, 
especially in relation to diagnosis of diabetes, as well as   
systematically securing that hospitalized patients receive 
adequate prescription at discharge. 
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